The DNA Resource Core was founded in 1999 and has been continuously funded by the CCSG as a DF/HCC Shared Resources since 2000. The facility is currently led by J. Wade Harper and is jointly managed (Cancer Center and Institution). The Core provides investigators access to specialized resources such as informatics support, rapid and user-friendly high-throughput DNA sequencing services and cDNA/RNAi clone repository and distribution services. The success of the DNA Resource Core is evidenced by its usage, sequencing about 200,000 samples per year. In 2004, the PlasmID DNA repository and associated in-house plasmid database was added. This repository's current collection includes more than 241,000 plasmid DNA clones useful for cloning, mutagenesis and expression relevant to more than 25 different species, with the emphasis on human cancer-related gene collections. In addition, based on the expressed need of DF/HCC members, the DNA Resource Core has now integrated shRNA libraries into the PlasmID DNA repository. Director: J. Wade Harper, PhD(HMS) Category: 1.2 (Molecular Biology) Management: Joint (Cancer Center and Institution)

Public Health Relevance

The DNA Resource Core was created to address the sequencing needs of both small-and large-scale DNA sequencing users in DF/HCC. The Core's mission is to provide quality and priority access to specialized resources and services. These services constitute an integral component of the vast majority of basic and translational sciences being done under the umbrella of DF/HCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006516-47
Application #
8228333
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-05-15
Budget End
2012-11-30
Support Year
47
Fiscal Year
2012
Total Cost
$300,897
Indirect Cost
$69,349
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Chen, Yi-Bin; Batchelor, Tracy; Li, Shuli et al. (2015) Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer 121:226-33
Waldron, Levi; Haibe-Kains, Benjamin; Culhane, Aedín C et al. (2014) Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst 106:
Yilmazel, Bahar; Hu, Yanhui; Sigoillot, Frederic et al. (2014) Online GESS: prediction of miRNA-like off-target effects in large-scale RNAi screen data by seed region analysis. BMC Bioinformatics 15:192
Mazzola, Emanuele; Chipman, Jonathan; Cheng, Su-Chun et al. (2014) Recent BRCAPRO upgrades significantly improve calibration. Cancer Epidemiol Biomarkers Prev 23:1689-95
Zhao, Sihai Dave; Parmigiani, Giovanni; Huttenhower, Curtis et al. (2014) Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis. Bioinformatics 30:3062-9
Parkhitko, Andrey A; Priolo, Carmen; Coloff, Jonathan L et al. (2014) Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide. Mol Cancer Res 12:48-57
Cheng, Long; Desai, Jigar; Miranda, Carlos J et al. (2014) Human CFEOM1 mutations attenuate KIF21A autoinhibition and cause oculomotor axon stalling. Neuron 82:334-49
Akbay, Esra A; Moslehi, Javid; Christensen, Camilla L et al. (2014) D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 28:479-90
Brunner, Andrew M; Blonquist, Traci M; Sadrzadeh, Hossein et al. (2014) Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. Leuk Res 38:773-80
Karamichos, D; Hutcheon, A E K; Rich, C B et al. (2014) In vitro model suggests oxidative stress involved in keratoconus disease. Sci Rep 4:4608

Showing the most recent 10 out of 177 publications